Lucyd, Inc (NASDAQ: LUCYW) Stock Competitors & Peer Comparison
See LUCYW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LUCYW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LUCYW | $0.06 | +5.09% | 296.1K | -0.00 | -$378.22 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
LUCYW vs BDX Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas BDX's P/E ratio is 11.62. In terms of profitability, LUCYW's ROE is -0.83%, compared to BDX's ROE of +0.05%. Regarding short-term risk, LUCYW is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
LUCYW vs BDXA Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas BDXA's P/E ratio is 45.70. In terms of profitability, LUCYW's ROE is -0.83%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, LUCYW is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
LUCYW vs MDLN Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas MDLN's P/E ratio is 45.06. In terms of profitability, LUCYW's ROE is -0.83%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, LUCYW is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
LUCYW vs WST Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas WST's P/E ratio is 41.19. In terms of profitability, LUCYW's ROE is -0.83%, compared to WST's ROE of +0.19%. Regarding short-term risk, LUCYW is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
LUCYW vs HOLX Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas HOLX's P/E ratio is 31.54. In terms of profitability, LUCYW's ROE is -0.83%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, LUCYW is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
LUCYW vs COO Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas COO's P/E ratio is 15.42. In terms of profitability, LUCYW's ROE is -0.83%, compared to COO's ROE of +0.03%. Regarding short-term risk, LUCYW is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
LUCYW vs BDXB Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas BDXB's P/E ratio is 7.60. In terms of profitability, LUCYW's ROE is -0.83%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, LUCYW is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
LUCYW vs BAX Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas BAX's P/E ratio is 10.77. In terms of profitability, LUCYW's ROE is -0.83%, compared to BAX's ROE of -0.16%. Regarding short-term risk, LUCYW is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
LUCYW vs ATR Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ATR's P/E ratio is 23.13. In terms of profitability, LUCYW's ROE is -0.83%, compared to ATR's ROE of +0.14%. Regarding short-term risk, LUCYW is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
LUCYW vs AVTR Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas AVTR's P/E ratio is 13.46. In terms of profitability, LUCYW's ROE is -0.83%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, LUCYW is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
LUCYW vs RGEN Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas RGEN's P/E ratio is 73.31. In terms of profitability, LUCYW's ROE is -0.83%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, LUCYW is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
LUCYW vs TFX Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas TFX's P/E ratio is 12.32. In terms of profitability, LUCYW's ROE is -0.83%, compared to TFX's ROE of -0.28%. Regarding short-term risk, LUCYW is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
LUCYW vs BLCO Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas BLCO's P/E ratio is 24.88. In terms of profitability, LUCYW's ROE is -0.83%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, LUCYW is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
LUCYW vs STVN Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas STVN's P/E ratio is 31.81. In terms of profitability, LUCYW's ROE is -0.83%, compared to STVN's ROE of +0.10%. Regarding short-term risk, LUCYW is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
LUCYW vs MMSI Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas MMSI's P/E ratio is 19.01. In terms of profitability, LUCYW's ROE is -0.83%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, LUCYW is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
LUCYW vs ICUI Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ICUI's P/E ratio is 19.66. In terms of profitability, LUCYW's ROE is -0.83%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, LUCYW is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
LUCYW vs HAE Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas HAE's P/E ratio is 15.86. In terms of profitability, LUCYW's ROE is -0.83%, compared to HAE's ROE of +0.11%. Regarding short-term risk, LUCYW is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
LUCYW vs XRAY Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas XRAY's P/E ratio is 9.04. In terms of profitability, LUCYW's ROE is -0.83%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, LUCYW is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
LUCYW vs LMAT Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas LMAT's P/E ratio is 37.05. In terms of profitability, LUCYW's ROE is -0.83%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, LUCYW is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
LUCYW vs PLSE Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas PLSE's P/E ratio is -27.48. In terms of profitability, LUCYW's ROE is -0.83%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, LUCYW is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
LUCYW vs ATRC Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, LUCYW's ROE is -0.83%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, LUCYW is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
LUCYW vs BLFS Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas BLFS's P/E ratio is -141.85. In terms of profitability, LUCYW's ROE is -0.83%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, LUCYW is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
LUCYW vs AZTA Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas AZTA's P/E ratio is 60.82. In terms of profitability, LUCYW's ROE is -0.83%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, LUCYW is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
LUCYW vs KMTS Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas KMTS's P/E ratio is -8.92. In terms of profitability, LUCYW's ROE is -0.83%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, LUCYW is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
LUCYW vs STAA Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas STAA's P/E ratio is 41.02. In terms of profitability, LUCYW's ROE is -0.83%, compared to STAA's ROE of -0.06%. Regarding short-term risk, LUCYW is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
LUCYW vs QDEL Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas QDEL's P/E ratio is 11.98. In terms of profitability, LUCYW's ROE is -0.83%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, LUCYW is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
LUCYW vs ATRI Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ATRI's P/E ratio is 64.50. In terms of profitability, LUCYW's ROE is -0.83%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, LUCYW is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
LUCYW vs ANGO Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ANGO's P/E ratio is -34.85. In terms of profitability, LUCYW's ROE is -0.83%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, LUCYW is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
LUCYW vs NNNN Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas NNNN's P/E ratio is 145.38. In terms of profitability, LUCYW's ROE is -0.83%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, LUCYW is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
LUCYW vs OSUR Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas OSUR's P/E ratio is -4.78. In terms of profitability, LUCYW's ROE is -0.83%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, LUCYW is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
LUCYW vs SMTI Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas SMTI's P/E ratio is -426.00. In terms of profitability, LUCYW's ROE is -0.83%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, LUCYW is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
LUCYW vs UTMD Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas UTMD's P/E ratio is 19.86. In terms of profitability, LUCYW's ROE is -0.83%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, LUCYW is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
LUCYW vs INFU Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas INFU's P/E ratio is 23.97. In terms of profitability, LUCYW's ROE is -0.83%, compared to INFU's ROE of +0.14%. Regarding short-term risk, LUCYW is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
LUCYW vs KRMD Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas KRMD's P/E ratio is -95.75. In terms of profitability, LUCYW's ROE is -0.83%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, LUCYW is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
LUCYW vs PDEX Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas PDEX's P/E ratio is 19.34. In terms of profitability, LUCYW's ROE is -0.83%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, LUCYW is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
LUCYW vs MBOT Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas MBOT's P/E ratio is -6.58. In terms of profitability, LUCYW's ROE is -0.83%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, LUCYW is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
LUCYW vs AKYA Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas AKYA's P/E ratio is -1.34. In terms of profitability, LUCYW's ROE is -0.83%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, LUCYW is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
LUCYW vs STSS Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas STSS's P/E ratio is -0.02. In terms of profitability, LUCYW's ROE is -0.83%, compared to STSS's ROE of -1.66%. Regarding short-term risk, LUCYW is more volatile compared to STSS. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
LUCYW vs DXR Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas DXR's P/E ratio is 27.33. In terms of profitability, LUCYW's ROE is -0.83%, compared to DXR's ROE of +0.22%. Regarding short-term risk, LUCYW is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
LUCYW vs OMIC Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas OMIC's P/E ratio is -0.58. In terms of profitability, LUCYW's ROE is -0.83%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, LUCYW is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
LUCYW vs IGAP Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas IGAP's P/E ratio is -10.52. In terms of profitability, LUCYW's ROE is -0.83%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, LUCYW is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
LUCYW vs NEPH Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas NEPH's P/E ratio is 50.86. In terms of profitability, LUCYW's ROE is -0.83%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, LUCYW is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
LUCYW vs MLSS Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas MLSS's P/E ratio is -6.50. In terms of profitability, LUCYW's ROE is -0.83%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, LUCYW is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
LUCYW vs POCI Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas POCI's P/E ratio is -6.07. In terms of profitability, LUCYW's ROE is -0.83%, compared to POCI's ROE of -0.37%. Regarding short-term risk, LUCYW is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
LUCYW vs SDC Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas SDC's P/E ratio is -0.03. In terms of profitability, LUCYW's ROE is -0.83%, compared to SDC's ROE of -1.96%. Regarding short-term risk, LUCYW is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for LUCYW.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
LUCYW vs HBIO Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas HBIO's P/E ratio is -16.81. In terms of profitability, LUCYW's ROE is -0.83%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, LUCYW is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
LUCYW vs IVC Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas IVC's P/E ratio is -0.79. In terms of profitability, LUCYW's ROE is -0.83%, compared to IVC's ROE of -0.46%. Regarding short-term risk, LUCYW is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
LUCYW vs RVP Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas RVP's P/E ratio is -2.06. In terms of profitability, LUCYW's ROE is -0.83%, compared to RVP's ROE of -0.08%. Regarding short-term risk, LUCYW is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
LUCYW vs ZJYL Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, LUCYW's ROE is -0.83%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, LUCYW is more volatile compared to ZJYL. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
LUCYW vs FEMY Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas FEMY's P/E ratio is -10.25. In terms of profitability, LUCYW's ROE is -0.83%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, LUCYW is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
LUCYW vs RGNT Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas RGNT's P/E ratio is -0.08. In terms of profitability, LUCYW's ROE is -0.83%, compared to RGNT's ROE of N/A. Regarding short-term risk, LUCYW is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
LUCYW vs NSTG Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas NSTG's P/E ratio is -0.03. In terms of profitability, LUCYW's ROE is -0.83%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, LUCYW is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for LUCYW.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
LUCYW vs NXGL Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas NXGL's P/E ratio is -1.13. In terms of profitability, LUCYW's ROE is -0.83%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, LUCYW is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
LUCYW vs POAI Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas POAI's P/E ratio is -0.03. In terms of profitability, LUCYW's ROE is -0.83%, compared to POAI's ROE of -107.05%. Regarding short-term risk, LUCYW is more volatile compared to POAI. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
LUCYW vs LUCY Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas LUCY's P/E ratio is -0.39. In terms of profitability, LUCYW's ROE is -0.83%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, LUCYW is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
LUCYW vs MHUA Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas MHUA's P/E ratio is 0.25. In terms of profitability, LUCYW's ROE is -0.83%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, LUCYW is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
LUCYW vs NXGLW Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, LUCYW's ROE is -0.83%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, LUCYW is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
LUCYW vs GMVD Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas GMVD's P/E ratio is -0.01. In terms of profitability, LUCYW's ROE is -0.83%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, LUCYW is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for LUCYW.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
LUCYW vs GMVDW Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas GMVDW's P/E ratio is N/A. In terms of profitability, LUCYW's ROE is -0.83%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, LUCYW is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for LUCYW.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
LUCYW vs AVGR Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas AVGR's P/E ratio is -0.05. In terms of profitability, LUCYW's ROE is -0.83%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, LUCYW is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for LUCYW.Check AVGR's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
LUCYW vs GCTK Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas GCTK's P/E ratio is -0.01. In terms of profitability, LUCYW's ROE is -0.83%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, LUCYW is more volatile compared to GCTK. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check GCTK's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
LUCYW vs HRC Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, HRC has a market cap of 0. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas HRC's P/E ratio is 41.92. In terms of profitability, LUCYW's ROE is -0.83%, compared to HRC's ROE of +0.14%. Regarding short-term risk, LUCYW is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
LUCYW vs ALOG Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ALOG has a market cap of 0. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ALOG's P/E ratio is 40.93. In terms of profitability, LUCYW's ROE is -0.83%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, LUCYW is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
LUCYW vs ATRS Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, ATRS has a market cap of 0. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas ATRS's P/E ratio is 14.95. In terms of profitability, LUCYW's ROE is -0.83%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, LUCYW is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check ATRS's competition here
Apria, Inc. (NASDAQ: APR)
LUCYW vs APR Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, APR has a market cap of 0. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas APR's P/E ratio is 22.59. In terms of profitability, LUCYW's ROE is -0.83%, compared to APR's ROE of +9.81%. Regarding short-term risk, LUCYW is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
LUCYW vs IIN Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, IIN has a market cap of 0. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas IIN's P/E ratio is 226.45. In terms of profitability, LUCYW's ROE is -0.83%, compared to IIN's ROE of -0.00%. Regarding short-term risk, LUCYW is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check IIN's competition here
Invuity, Inc. (NASDAQ: IVTY)
LUCYW vs IVTY Comparison July 2026
Lucyd, Inc (NASDAQ: LUCYW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LUCYW stands at 296.1K. In comparison, IVTY has a market cap of 0. Regarding current trading prices, LUCYW is priced at $0.06 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LUCYW currently has a P/E ratio of -0.00, whereas IVTY's P/E ratio is -3.80. In terms of profitability, LUCYW's ROE is -0.83%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, LUCYW is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for LUCYW.Check IVTY's competition here